Mediclinic International plc Director/PDMR Shareholding (7232P)

TIDMMDC

RNS Number : 7232P

Mediclinic International plc

30 May 2018

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

30 May 2018

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 24 and 25 May 2018, Mr Danie Meintjes, Chief Executive Officer of Mediclinic International plc, sold a total of 49 423 shares in the Company, being the shares awarded to Mr Meintjes in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017. Mr Meintjes retained the totality of the shares at the time but has now disposed of them to cover personal tax liabilities. Mr Meintjes continues to hold 123 900 shares in the Company.

The notification below is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

 
 1.   Details of PDMR / person closely associated 
       with them ("PCA") 
---  ----------------------------------------------------------- 
 a)   Name                   Mr Daniël Petrus Meintjes 
---  ---------------------  ------------------------------------ 
 2.   Reason for the notification 
---  ----------------------------------------------------------- 
 a)   Position               Chief Executive Officer of the 
       / status               Company 
---  ---------------------  ------------------------------------ 
 b)   Initial notification   Initial Notification 
       / amendment 
---  ---------------------  ------------------------------------ 
 3.   Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ----------------------------------------------------------- 
 a)   Name                   Mediclinic International plc 
---  ---------------------  ------------------------------------ 
 b)   LEI                    2138002S5BSBIZTD5I60 
---  ---------------------  ------------------------------------ 
 4.   Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ----------------------------------------------------------- 
 a)   Description            Ordinary Shares 
       of the financial 
       instrument             GB00B8HX8Z88 
       Identification 
       Code 
---  ---------------------  ------------------------------------ 
 b)   Nature of              Sale of shares awarded in 2014 
       the transaction        under the Mediclinic International 
                              Limited Forfeitable Share Plan, 
                              which vested on 31 May 2017 
---  ---------------------  ------------------------------------ 
 c)   Price(s)                Price(s)                Volume(s) 
       and volume(s)          ----------------------  ---------- 
                               ZAR 110.01 per share    17 423 
                              ----------------------  ---------- 
---  ---------------------  ------------------------------------ 
 d)   Aggregated 
       information 
       Aggregated 
       volume                  17 423 
       Price 
                               ZAR 110.01 
---  ---------------------  ------------------------------------ 
 e)   Date of the            24 May 2018 
       transaction 
---  ---------------------  ------------------------------------ 
 f)   Place of               Johannesburg Stock Exchange 
       the transaction 
---  ---------------------  ------------------------------------ 
 4.   Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ----------------------------------------------------------- 
 a)   Description            Ordinary Shares 
       of the financial 
       instrument             GB00B8HX8Z88 
       Identification 
       Code 
---  ---------------------  ------------------------------------ 
 b)   Nature of              Sale of shares awarded in 2014 
       the transaction        under the Mediclinic International 
                              Limited Forfeitable Share Plan, 
                              which vested on 31 May 2017 
---  ---------------------  ------------------------------------ 
 c)   Price(s)                Price(s)                Volume(s) 
       and volume(s)          ----------------------  ---------- 
                               ZAR 107.01 per share    32 000 
                              ----------------------  ---------- 
---  ---------------------  ------------------------------------ 
 d)   Aggregated 
       information 
       Aggregated 
       volume                  32 000 
       Price 
                               ZAR 107.01 
---  ---------------------  ------------------------------------ 
 e)   Date of the            25 May 2018 
       transaction 
---  ---------------------  ------------------------------------ 
 f)   Place of               Johannesburg Stock Exchange 
       the transaction 
---  ---------------------  ------------------------------------ 
 

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBXGDUSSXBGIG

(END) Dow Jones Newswires

May 30, 2018 10:00 ET (14:00 GMT)